We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
The current XLO market cap is 28.64M. The company's latest EPS is USD -3.2032 and P/E is -0.32.
| Quarter End | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | ||
| Total Revenue | 0 | 0 | 0 | 0 | 0 |
| Operating Income | -24.55M | -20.21M | -23.17M | -23.53M | -20.12M |
| Net Income | -24.61M | -19.79M | -22.47M | -22.65M | -19.36M |
| Year End 31 December 2022 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Revenue | 0 | 0 | 0 | 0 |
| Operating Income | -19.03M | -54.56M | -75.04M | -89.15M |
| Net Income | -17.31M | -55.22M | -75.8M | -88.22M |
| Quarter End | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | ||
| Total Assets | 178.13M | 157.41M | 139.17M | 111.51M | 92.36M |
| Total Liabilities | 33.91M | 31.12M | 33.52M | 26.71M | 24.98M |
| Total Equity | 144.22M | 126.3M | 105.65M | 84.79M | 67.38M |
| Year End 31 December 2022 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Assets | 62.72M | 36.32M | 218.06M | 139.17M |
| Total Liabilities | 24.21M | 41.6M | 32.63M | 33.52M |
| Total Equity | -29.52M | -83.29M | 185.43M | 105.65M |
| Quarter End | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | ||
| Operating | -37.59M | -57.5M | -75.72M | -25.25M | -41.82M |
| Investing | -1.03M | -1.36M | -1.87M | -170k | -486k |
| Financing | -26k | -48k | -69k | -1.69M | -2.68M |
| Year End 31 December 2022 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Operating | -17.84M | -36.09M | -80.75M | -75.72M |
| Investing | -715k | -2.19M | -1.1M | -1.87M |
| Financing | 60.02M | 10.03M | 260.67M | -69k |
| Market Cap | 28.64M |
| Price to Earnings Ratio | -0.32 |
| Price to Sales Ratio | 0 |
| Price to Cash Ratio | 0.24 |
| Price to Book Ratio | 0.27 |
| Dividend Yield | - |
| Shares Outstanding | 27.54M |
| Average Volume (1 week) | 49.21k |
| Average Volume (1 Month) | 39.2k |
| 52 Week Change | -57.72% |
| 52 Week High | 4.92 |
| 52 Week Low | 0.85 |
| Spread (Intraday) | 0.32 (25.65%) |
| Company Name | Xilio Therapeutics Inc |
| Address |
1209 orange street wilmington, delaware 19801 |
| Website | https://xiliotx.com |
| Industry | pharmaceutical preparations (2834) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
|
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions Support: 1-888-992-3836 | help@advfn.com |
| ADVFN UK Investors Hub ADVFN Italy ADVFN Australia ADVFN Brazil |
| ADVFN Canada ADVFN Germany ADVFN Japan ADVFN Mexico |
| ADVFN France ADVFN US ADVFN Korea |
